Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. a [123I]IBZM SPET study
Pizzolato, G.; Cagnin, A.; Rossato, A.; Chierichetti, F.; Fabbri, M.; Dam, M.; Ferlin, G.; Battistin, L.
Advances in Neurology 69: 467-473
1996
ISSN/ISBN: 0091-3952 PMID: 8615167 Document Number: 459664
Document emailed within 1 workday
Related Documents
Buscaino, G.A.; Sori, A.; Campanella, G. 1972: Study of dopamine and noradrenaline in the brains of three patients with Parkinson's disease who died in the course of treatment with L-dopa Revue Neurologique (Paris) 127(2): 301-302Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Streifler, M.; Vardi, Y.; Kesten, M.; Oberman, Z.; Herzberg, M. 1972: Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease Israel Journal of Medical Sciences 81(5): 597-601
Fuchs, G. 1997: Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy Fortschritte der Medizin 115(5): 43-45
Hillegaart, V.; Ahlenius, S.; Fowler, C.J.; Magnusson, O. 1988: Increased duration of dopamine receptor antagonist-induced effects on both behaviour and striatal dopamine turnover by repeated testing in rats Pharmacology and Toxicology 63(2): 114-117
Calne, D.B.; Stoessl, A.J. 1987: Transmitter receptor alterations in Parkinson's disease Advances in Neurology 45: 45-49
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Bettin, S.; Kämpfer, I.; Seese, A.; Schäfer, A.; Reuter, M.; Lössner, J.; Dietrich, J.; Wagner, A.; Knapp, W.H. 1997: Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms Nuklearmedizin. Nuclear Medicine 36(5): 167-172
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
Dzudza, M.; Dzudza, D. 1974: Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease Medicinski Arhiv 28(4): 407-415
Butkerait, P.; Wang, H.Y.; Friedman, E. 1994: Increases in guanine nucleotide binding to striatal G proteins is associated with dopamine receptor supersensitivity Journal of Pharmacology and Experimental Therapeutics 271(1): 422-428
Mufson, E.J.; Kordower, J.H. 1989: Nerve growth factor receptor expressing human basal forebrain neurons: pathologic alterations in Alzheimer's and Parkinson's disease Progress in Clinical and Biological Research 317: 401-414
Ohnmacht, U.; Tränkle, C.; Mohr, K.; Gmeiner, P. 1999: 3H]Pramipexole: a selective radioligand for the high affinity dopamine D2 receptor in bovine striatal membranes Die Pharmazie 54(4): 294-297
Hilakivi, I.; Rinne, J.; Marjamäki, P. 1999: Effect of desipramine during infancy and preweanling on dorsal striatal dopamine D1 and D2 receptor binding in adolescence in the rat Polish Journal of Pharmacology 51(4): 311-316
Rubinstein, M.; Muschietti, J.P.; Gershanik, O.; Flawia, M.M.; Stefano, F.J. 1990: Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice Journal of Pharmacology and Experimental Therapeutics 252(2): 810-816
Suwantamee, J.; Nidhinandana, S.; Srisuwananukorn, S.; Laptikultham, S.; Pisarnpong, A.; Chankrachang, S.; Bundhukul, A. 2004: Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study Journal of the Medical Association of Thailand 87(11): 1293-1300
Christiani, K.; Möller, W.D. 1973: Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor Münchener Medizinische Wochenschrift 115(16): 711-713
Maggio, R.; Barbier, P.; Corsini, G.U. 1995: Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response Journal of Neural Transmission. Supplementum 45: 133-136
Dwoskin, L.P.; Zahniser, N.R. 1986: Robust modulation of [3H]dopamine release from rat striatal slices by D-2 dopamine receptors Journal of Pharmacology and Experimental Therapeutics 239(2): 442-453
Völler, G. 1970: L-dopa in the treatment of Parkinson's disease Die Medizinische Welt 27: 1267-1268